NASDAQ:MOLN Molecular Partners (MOLN) Stock Price, News & Analysis $7.35 +0.12 (+1.66%) (As of 07/1/2024 ET) Add Compare Share Share Today's Range$6.85▼$7.6350-Day Range$3.55▼$11.0152-Week Range$3.32▼$12.70Volume9,144 shsAverage Volume22,465 shsMarket Capitalization$269.60 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Molecular Partners alerts: Email Address Molecular Partners MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside38.8% Downside$4.50 Price TargetShort InterestBearish0.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.22) to ($1.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.07 out of 5 starsMedical Sector911th out of 916 stocksBiological Products, Except Diagnostic Industry151st out of 153 stocks 1.0 Analyst's Opinion Consensus RatingMolecular Partners has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMolecular Partners has received no research coverage in the past 90 days.Read more about Molecular Partners' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.31% of the outstanding shares of Molecular Partners have been sold short.Short Interest Ratio / Days to CoverMolecular Partners has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Molecular Partners has recently increased by 134.15%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMolecular Partners does not currently pay a dividend.Dividend GrowthMolecular Partners does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MOLN. Previous Next 1.9 News and Social Media Coverage News SentimentMolecular Partners has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Molecular Partners this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Molecular Partners insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.93% of the stock of Molecular Partners is held by insiders.Percentage Held by InstitutionsOnly 26.55% of the stock of Molecular Partners is held by institutions.Read more about Molecular Partners' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Molecular Partners are expected to grow in the coming year, from ($2.22) to ($1.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Partners is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Partners is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Partners has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Molecular Partners' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingBiden Debate DisasterBiden was a disaster in the debate. Trump looked 100% more presidential. Biden’s campaign is DONE… But there’s more to this story than meets the eye.Go here now to see why Trump won the debate, but will lose the election. About Molecular Partners Stock (NASDAQ:MOLN)Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Read More MOLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOLN Stock News HeadlinesJune 17, 2024 | globenewswire.comMolecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation SummitJune 14, 2024 | globenewswire.comMolecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024July 1, 2024 | Paradigm Press (Ad)Did Joe Biden just reveal his replacement?The Democrats are scheming to remove Biden as their presidential nominee… And absolute chaos will ensue.June 11, 2024 | globenewswire.comMolecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024June 1, 2024 | globenewswire.comMolecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024May 16, 2024 | globenewswire.comInterim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 ProgramMay 1, 2024 | seekingalpha.comMOLN Molecular Partners AGApril 29, 2024 | finance.yahoo.comMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of ActionJuly 1, 2024 | Paradigm Press (Ad)Did Joe Biden just reveal his replacement?The Democrats are scheming to remove Biden as their presidential nominee… And absolute chaos will ensue.April 29, 2024 | globenewswire.comMolecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of ActionApril 19, 2024 | globenewswire.comLife Science Cares Launches in SwitzerlandApril 18, 2024 | finance.yahoo.comWe Think Molecular Partners (VTX:MOLN) Needs To Drive Business Growth CarefullyApril 17, 2024 | globenewswire.comMolecular Partners Announces All Board Proposals Approved at the Annual General MeetingApril 4, 2024 | bizjournals.comBeyond Benign, MilliporeSigma partner on green chemistryMarch 26, 2024 | globenewswire.comMolecular Partners Publishes Invitation to Annual General Meeting 2024March 21, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Hold Rating on Molecular Partners (MOLN)March 14, 2024 | globenewswire.comMolecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023March 13, 2024 | markets.businessinsider.comMolecular Partners AG (spons. ADRs) hosts conference call for investorsMarch 13, 2024 | finance.yahoo.comThe past three years for Molecular Partners (VTX:MOLN) investors has not been profitableMarch 2, 2024 | uk.investing.comMolecular Partners wins dismissal of securities lawsuitMarch 1, 2024 | globenewswire.comMolecular Partners Announces Dismissal of Class Action LawsuitMarch 1, 2024 | globenewswire.comMolecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor PresentationsJanuary 7, 2024 | finance.yahoo.comMolecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 5, 2024 | msn.comMolecular Partners, Orano to collaborate on RDT therapies for cancerDecember 31, 2023 | ca.finance.yahoo.comMolecular Partners AG (6ML0.MU)December 10, 2023 | finance.yahoo.comMolecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingNovember 11, 2023 | morningstar.comMolecular Partners AG ADR MOLNSee More Headlines Receive MOLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today7/01/2024Next Earnings (Estimated)8/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MOLN CUSIPN/A CIK1745114 Webwww.molecularpartners.com Phone41-44-755-7700FaxN/AEmployees167Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$4.50 Low Stock Price Target$4.50 Potential Upside/Downside-38.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,040,000.00 Net Margins-864.64% Pretax Margin-864.69% Return on Equity-31.42% Return on Assets-28.20% Debt Debt-to-Equity RatioN/A Current Ratio14.68 Quick Ratio14.68 Sales & Book Value Annual Sales$7.84 million Price / Sales34.39 Cash FlowN/A Price / Cash FlowN/A Book Value$5.41 per share Price / Book1.36Miscellaneous Outstanding Shares36,680,000Free Float34,507,000Market Cap$269.60 million OptionableNot Optionable Beta1.04 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Patrick Amstutz Ph.D. (Age 49)Co-Founder, CEO, Member of Management Board & Director Comp: $735.02kDr. Michael Tobias Stumpp Ph.D. (Age 52)Co-Founder, Executive VP of Projects & Member of Management Board Mr. Robert HendriksSenior VP of FinanceMr. Alexander Zurcher (Age 49)COO & Member of Management Board Ms. Renate Gloggner (Age 54)Executive VP of People & Community and Member of Management Board Mr. Daniel Steiner Ph.D.Senior Vice President of Research & TechnologyMr. Seth D. LewisSenior Vice President of Investor Relations, Communications & StrategyMr. Michael PitznerGeneral Counsel, Compliance Officer, Senior VP Legal & Business DevelopmentDr. Pamela A. Trail Ph.D. (Age 68)Strategic Consultant Ms. Anne Goubier D.V.M.Ph.D., Senior Vice President of Research & Early DevelopmentMore ExecutivesKey CompetitorsAdaptimmune TherapeuticsNASDAQ:ADAPHarpoon TherapeuticsNASDAQ:HARPAdverum BiotechnologiesNASDAQ:ADVMKaryopharm TherapeuticsNASDAQ:KPTIKodiak SciencesNASDAQ:KODView All Competitors MOLN Stock Analysis - Frequently Asked Questions Should I buy or sell Molecular Partners stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Molecular Partners in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MOLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOLN, but not buy additional shares or sell existing shares. View MOLN analyst ratings or view top-rated stocks. What is Molecular Partners' stock price target for 2024? 1 Wall Street analysts have issued 12-month target prices for Molecular Partners' shares. Their MOLN share price targets range from $4.50 to $4.50. On average, they predict the company's share price to reach $4.50 in the next year. This suggests that the stock has a possible downside of 38.8%. View analysts price targets for MOLN or view top-rated stocks among Wall Street analysts. How have MOLN shares performed in 2024? Molecular Partners' stock was trading at $4.18 on January 1st, 2024. Since then, MOLN shares have increased by 75.8% and is now trading at $7.35. View the best growth stocks for 2024 here. Are investors shorting Molecular Partners? Molecular Partners saw a increase in short interest in June. As of June 15th, there was short interest totaling 115,200 shares, an increase of 134.1% from the May 31st total of 49,200 shares. Based on an average trading volume of 25,100 shares, the days-to-cover ratio is currently 4.6 days. View Molecular Partners' Short Interest. When is Molecular Partners' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 28th 2024. View our MOLN earnings forecast. How were Molecular Partners' earnings last quarter? Molecular Partners AG (NASDAQ:MOLN) posted its earnings results on Thursday, May, 16th. The company reported ($0.39) earnings per share (EPS) for the quarter. The firm had revenue of $3.13 million for the quarter. Molecular Partners had a negative net margin of 864.64% and a negative trailing twelve-month return on equity of 31.42%. When did Molecular Partners IPO? Molecular Partners (MOLN) raised $81 million in an IPO on Wednesday, June 16th 2021. The company issued 3,000,000 shares at a price of $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager. How do I buy shares of Molecular Partners? Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MOLN) was last updated on 7/1/2024 by MarketBeat.com Staff From Our Partners1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBiden Debate DisasterBiden was a disaster in the debate. Trump looked 100% more presidential. Biden’s campaign is DONE… But t...Banyan Hill Publishing | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredCatalyst Could Trigger 10,000% Crypto GainsFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredWhere AI is REALLY Going NextBuying Nvidia was a good idea – twenty years ago when I first recommended it (for up to 37,000% gains). But...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.